Expression of TIM-3 on Lymphocytes in Sepsis

• Conditions: Immunosuppression; Sepsis

• Registration Number: NCT02319876
• Lead Sponsor: Changhai Hospital

Brief Summary

The current project was designed to examine the express TIM-3 on lymphocytes and monocytes and its role in immunosuppression during sepsis.

Detailed Description

Immunosuppression is the leading cause of death in septic patients.Lymphocyte apoptosis has been recognized as an important step in the pathogenesis of sepsis. Previous studies indicated that T cell immunoglobulin and mucin protein 3 (TIM-3) is a type I cell surface protein and was identified as a marker of lymphocyte dysfunction. The current project was designed to examine the express TIM-3 on lymphocytes and monocytes and its further role in immunosuppression during sepsis.

Study Timeline

• Study Start: 2014-02
• Study First Submitted: 2014-12-15
• Study First Submitted QC: 2014-12-15
• Study First Posted: 2014-12-18
• Status Verified: 2015-06
• Last Update Submitted: 2015-07-27
• Last Update Posted: 2015-07-29
• Primary Completion: 2015-12
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• patients with severe sepsis
• patients undergo invasive spine surgery
• healthy volunteers

Exclusion Criteria

• patients with immunodeficient diseases
• patients who accept glucocorticoid or immunosuppressant
• patients with an age older than 18 years
• patients providing the informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
TIM-3 expression on CD4+, CD8+ T cells and CD14+ monocytes	within 24h after recruitment	TIM-3 level on T cells was compared between different populations.

Secondary Outcome Measures

Name	Time	Method
28-day mortality	28 days after diagnosis of sepsis

Trial Locations

Locations (1)

Anesthesiology and Intensive Care, Changhai Hospital; 🇨🇳 Shanghai, Shanghai, China